Reference chart
Every compound in one table. Tap a column heading to sort. Open a compound for sources and detail.
| Compound | Category | Evidence | US FDA status | Sports (WADA) | Size |
|---|---|---|---|---|---|
| Bone & mineral | FDA-approved | FDA-approved as Tymlos (2017) for osteoporosis in postmenopausal women and men at high fracture risk. No… | Not named on the 2026 WADA Prohibited List. | 34 amino acids (includes one non-standard residue, Aib, at position 29; C-terminal amide) | |
| Neuro & cognitive | Preclinical only | Not FDA-approved; no FDA evaluation found. | Not named on the 2026 Prohibited List. As a substance with no… | — | |
| Sexual health & melanocortin | FDA-approved | FDA-approved as Scenesse (afamelanotide implant) on October 8, 2019 to increase pain-free light exposure in… | Not named on the 2026 List; as an approved drug it is not an S0… | 13 amino acids | |
| Cosmetic & skin | Preclinical only | Not FDA-approved. Sold as a cosmetic ingredient; under FDA rules, a product claiming to regrow hair or… | Not named on the 2026 Prohibited List. As a cosmetic ingredient it… | 3 amino acids (plus a copper ion) | |
| Longevity & mitochondrial | Late-stage trials | Not FDA-approved (acadesine was investigated but never approved). | Prohibited at all times: named as an example of AMPK activators… | — | |
| Metabolic & weight | Early human data | Not FDA-approved for any use. | Prohibited at all times: listed by name under S2.2.3 (growth hormone… | 16 amino acids | |
| Pain & nerve | Early human data | Not FDA-approved; investigational | Not named on the 2026 Prohibited List; as a substance with no… | 11 amino acids (N-terminal pyroglutamate) | |
| Cosmetic & skin | Early human data | Not an FDA-approved drug. Sold as a cosmetic ingredient; anti-wrinkle claims that suggest changing body… | Not listed. | 6 amino acids (N-acetylated, C-terminal amide) | |
| Cardiovascular & blood | FDA-approved | FDA-approved (Angiomax, 2000; generics available) as an anticoagulant during PCI, including in patients with… | Not named on the 2026 WADA Prohibited List. | 20 amino acids (N-terminal D-Phe) | |
| Tissue repair | Early human data | Not FDA-approved for any use. | Prohibited at all times; named as an example under S0 (Non-Approved… | 15 amino acids | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Metabolic & weight | Late-stage trials | Investigational; not FDA-approved. New Drug Application for CagriSema submitted December 2025; FDA review… | Not named on the WADA list; as an unapproved drug it would fall… | Lipidated amylin analog | |
| Bone & mineral | FDA-approved | FDA-approved (Miacalcin injection, 1975; nasal spray products) for Paget's disease, hypercalcemia and… | Not named on the 2026 WADA Prohibited List. | 32 amino acids (disulfide ring between Cys1 and Cys7; C-terminal amide) | |
| Cardiovascular & blood | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Neuro & cognitive | Late-stage trials | Not FDA-approved; it has never been registered for use in the United States. | Not named on the 2026 Prohibited List. Because it is approved as a… | Mixture of low-molecular-weight peptides and free amino acids (not a single peptide) | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 3 amino acids | |
| Growth hormone axis | Early human data | Not FDA-approved; development discontinued | Prohibited at all times (S2.2.4 GHRH and analogues; CJC-1295 named) | 29 amino acids (GHRH 1-29 analogue with substitutions at positions 2, 8, 15 and 27); DAC form adds a maleimido-propionic acid–lysine linker | |
| Neuro & cognitive | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Immune & antimicrobial | FDA-approved | FDA-approved (Sandimmune, 1983; Neoral and generics) for prevention of organ rejection, and Neoral/generics… | Not named on the 2026 WADA Prohibited List. | 11 amino acids, cyclic (N-methylated; one D-alanine and the unusual residue MeBmt) | |
| Infection & antiviral | FDA-approved | FDA-approved (Cubicin, 2003; generics available) for complicated skin infections and S. aureus bacteremia. | Not named on the 2026 WADA Prohibited List (antibiotic). | 13 amino acids (cyclic lipopeptide with an N-decanoyl fatty-acid tail; includes non-standard residues) | |
| Endocrine (other) | FDA-approved | FDA-approved (first US approval 1978) as injection, tablets, nasal spray and Nocdurna sublingual tablets | Prohibited at all times — S5 Diuretics and masking agents (2026 List) | 9 residues (cyclic) | |
| Pain & nerve | FDA-approved | FDA-approved (Korsuva, 2021) for moderate-to-severe CKD-associated pruritus in adults on hemodialysis. | Not named on the 2026 WADA Prohibited List. | 4 D-amino acids plus a 4-aminopiperidine-4-carboxylic acid unit | |
| Neuro & cognitive | Preclinical only | Not FDA-approved; no human trials | Not named on the 2026 Prohibited List; as a substance with no… | Modified dipeptide (Tyr-Ile) with an N-terminal hexanoyl group and C-terminal aminohexanoic amide | |
| Neuro & cognitive | Early human data | Not FDA-approved. | Not named on the 2026 List. Likely captured by S0 (non-approved… | 9 amino acids | |
| Metabolic & weight | FDA-approved | FDA-approved as Trulicity (Eli Lilly): type 2 diabetes in adults (2014), cardiovascular risk reduction… | Not prohibited. WADA kept GLP-1 receptor agonists off its Prohibited… | Two identical chains, each a GLP-1 analog joined by a linker to a modified human IgG4 antibody Fc fragment (about 63 kDa in total) | |
| Metabolic & weight | Late-stage trials | Investigational; not FDA-approved (phase 3 trials ongoing as of Oct 2026). | Not named on the WADA list; as an unapproved drug it falls under S0… | — | |
| Infection & antiviral | FDA-approved | FDA-approved (Fuzeon, 2003) for HIV-1 in treatment-experienced patients with ongoing viral replication. | Not named on the 2026 WADA Prohibited List. | 36 amino acids (N-acetylated, C-terminal amide) | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved. | Not named. Likely captured by S0 (non-approved substances,… | 4 amino acids | |
| Cardiovascular & blood | FDA-approved | FDA-approved (Integrilin, 1998; generics available) for acute coronary syndrome and PCI. | Not named on the 2026 WADA Prohibited List. | Cyclic heptapeptide (6 amino acids + 1 mercaptopropionyl residue, disulfide-bridged) | |
| Metabolic & weight | FDA-approved | FDA-approved (Byetta 2005; Bydureon later); US brands Byetta and Bydureon BCise discontinued October 2024 | Not listed by name on the 2026 Prohibited List | 39 amino acids | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved; no published human trials. | Not named on the 2026 Prohibited List. As a substance with no… | — | |
| Longevity & mitochondrial | Early human data | Not FDA-approved as a drug; widely sold as a cosmetic ingredient. | Not specifically named on the 2026 Prohibited List. | 3 amino acids (plus a copper ion) | |
| Growth hormone axis | Early human data | Not FDA-approved in the US | Prohibited at all times (S2.2.4 GHRPs; GHRP-2/pralmorelin named) | 6 amino acids (hexapeptide, includes D-amino acids) | |
| Growth hormone axis | Early human data | Not FDA-approved | Prohibited at all times (S2.2.4 GHRPs; GHRP-6 named) | 6 amino acids (hexapeptide, includes D-amino acids) | |
| Metabolic & weight | FDA-approved | FDA-approved (first US approval 1960); injectable, ready-to-use and nasal (Baqsimi, 2019) forms | Not listed by name on the 2026 Prohibited List | 29 amino acids | |
| Antioxidant | Early human data | Not FDA-approved as a drug for any indication. Sold as a dietary supplement (oral). | Not named on the 2026 WADA Prohibited List, but IV infusions or… | 3 amino acids (tripeptide with an unusual γ-glutamyl bond) | |
| Hormonal & reproductive | FDA-approved | FDA-approved as Factrel (NDA 018123, Sept 30, 1982); now discontinued in the US. | Prohibited at all times under S2.2.1 (testosterone-stimulating… | 10 amino acids | |
| Growth hormone axis | Early human data | Not FDA-approved | Prohibited at all times (S2.2.4 GHRPs; examorelin/hexarelin named) | 6 amino acids (hexapeptide) | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved; investigational/research use only. | Not named. Likely captured by S0 (non-approved substances,… | 24 amino acids (21 if translated inside mitochondria) | |
| Growth hormone axis | Preclinical only | Not FDA-approved | Prohibited at all times (S2.3 growth factors: IGF-1 and its analogues) | — | |
| Metabolic & weight | FDA-approved | FDA-approved: human insulin since 1982 (Humulin), lispro 1996, glargine 2000, once-weekly icodec (Awiqli)… | Prohibited at all times — S4.4.2 Insulins and insulin-mimetics (2026… | 51 amino acids in two chains (human insulin); analogs differ by a few residues | |
| Growth hormone axis | Early human data | Not FDA-approved | Prohibited at all times (S2.2.4 growth hormone secretagogues; named) | 5 amino acids (pentapeptide, includes non-natural residues) | |
| Hormonal & reproductive | Early human data | Not FDA-approved. | Prohibited at all times under S2.2.1 (testosterone-stimulating… | 10 amino acids | |
| Immune & antimicrobial | Preclinical only | Not FDA-approved. | Not specifically named on the 2026 list; as an unapproved substance… | 3 amino acids | |
| Metabolic & weight | FDA-approved | FDA-approved as levocarnitine (Carnitor tablets 1985; oral solution and injection later) for carnitine… | Not prohibited as a substance. However, IV infusions or injections… | — | |
| Gastrointestinal | Late-stage trials | Not FDA-approved; development for celiac disease halted in 2022 after a phase 3 interim analysis did not… | Not named on the 2026 Prohibited List; as a substance with no… | 8 amino acids | |
| Hormonal & reproductive | FDA-approved | FDA-approved (Lupron Depot, 1989, and several other leuprolide products) for advanced prostate cancer; other… | Prohibited at all times in males (2026 List, S2.2.1… | 9 residues (nonapeptide; D-Leu at position 6, C-terminal ethylamide) | |
| Gastrointestinal | FDA-approved | FDA-approved as Linzess (2012); pediatric indications added through 2026 | Not listed by name on the 2026 Prohibited List | 14 amino acids (three disulfide bonds) | |
| Metabolic & weight | FDA-approved | FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014; adolescents 12+ in… | Not prohibited; GLP-1 drugs are not on the WADA Prohibited List… | GLP-1 analog with a C16 fatty-acid side chain | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Immune & antimicrobial | Early human data | Not FDA-approved; investigational | Not named on the 2026 Prohibited List; as a substance with no… | 37 amino acids | |
| Growth hormone axis | FDA-approved | FDA-approved (Macrilen, December 20, 2017) for diagnosing adult growth hormone deficiency | Prohibited at all times (S2.2.4 growth hormone secretagogues;… | Peptidomimetic (modified tripeptide-like molecule) | |
| Metabolic & weight | Late-stage trials | Not FDA-approved; investigational in the US. | Not named on the WADA list; would likely fall under S0 (non-approved… | Synthetic dual-agonist peptide | |
| Growth hormone axis | FDA-approved | FDA-approved (Increlex, 2005) for severe primary IGF-1 deficiency in children | Prohibited at all times (S2.3 growth factors: IGF-1/mecasermin named) | 70 amino acids | |
| Tissue repair | Preclinical only | Not FDA-approved; no approved drug contains MGF or PEG-MGF. | Prohibited at all times: mechano growth factors (MGFs) are named… | Synthetic MGF peptide: 24 amino acids (MGF-24aa-E); PEG-MGF is a pegylated version | |
| Sexual health & melanocortin | Early human data | Not FDA-approved for any use; FDA warned a seller in 2007 for marketing it as an unapproved, misbranded drug. | Not named on the 2026 List. Likely captured by S0 (non-approved… | 7 amino acids (cyclic) | |
| Hormonal & reproductive | FDA-approved | FDA-approved as Menopur (Ferring, 2004) for ART; regulated as a biologic since March 23, 2020. | Not named. Menotropins contains LH activity, and LH is prohibited at… | Mixture of two glycoprotein hormones (FSH and LH), each built from an alpha and a beta protein chain | |
| Growth hormone axis | Late-stage trials | Not FDA-approved; investigational (LUM-201) for pediatric GH deficiency | Prohibited at all times (S2.2.4 growth hormone secretagogues;… | Not a peptide (small molecule with a peptide-like substructure) | |
| Metabolic & weight | Preclinical only | Not FDA-approved for any use. | Prohibited at all times: listed by name under S4.4.1 (metabolic… | 16 amino acids | |
| Longevity & mitochondrial | Early human data | Not FDA-approved as a drug (NAD precursors such as nicotinamide riboside are sold as supplements). | Not named on the 2026 Prohibited List. | Not a peptide (dinucleotide coenzyme) | |
| Endocrine (other) | FDA-approved | FDA-approved: Sandostatin (1988), Sandostatin LAR Depot, Mycapssa oral capsules (2020); generics available | Not listed by name on the 2026 Prohibited List | 8 amino acids (cyclic) | |
| Metabolic & weight | FDA-approved | FDA-approved as Foundayo (April 1, 2026) for chronic weight management in adults with obesity, or overweight… | Not prohibited; GLP-1 drugs are not on the WADA Prohibited List… | Not a peptide (small molecule) | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 3 amino acids | |
| Hormonal & reproductive | FDA-approved | FDA-approved (oxytocin injection, e.g., Pitocin) for obstetric indications; approval date not verified in… | Not named on the 2026 Prohibited List. | 9 amino acids (with a disulfide ring) | |
| Neuro & cognitive | Preclinical only | Not FDA-approved; no human trials. | Not named on the 2026 Prohibited List. As a substance with no… | 7 amino acids | |
| Tissue repair | Preclinical only | Not FDA-approved. | Not named on the 2026 list, but it would likely fall under S0… | Reportedly 15 amino acids (BPC-157 sequence) as an arginine salt; not independently verified | |
| Neuro & cognitive | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 3 amino acids | |
| Immune & antimicrobial | Preclinical only | Not FDA-approved. FDA warned cancer patients not to buy or use PNC-27 products as a cancer treatment or cure… | Not named on the 2026 Prohibited List. As a substance with no… | 32 amino acids | |
| Metabolic & weight | FDA-approved | FDA-approved as Symlin (2005) as add-on to mealtime insulin in type 1 and type 2 diabetes | Not listed by name on the 2026 Prohibited List | 37 amino acids | |
| Hormonal & reproductive | Preclinical only | Not FDA-approved. FDA warning letter to Wholesale Peptide (June 17, 2026) states Prostamax sold with claims… | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Sexual health & melanocortin | FDA-approved | FDA-approved as Vyleesi (June 21, 2019) for acquired, generalized HSDD in premenopausal women. | Not named on the 2026 List; as an approved drug it is not an S0… | 7 amino acids (cyclic) | |
| Metabolic & weight | Late-stage trials | Investigational; not FDA-approved. Lilly plans to submit an application in Q1 2027. | Not named on the WADA list; as an unapproved drug it would fall… | Single peptide engineered to activate three receptors | |
| Neuro & cognitive | Early human data | Not FDA-approved. | Not named on the 2026 List. Because it is marketed in Russia,… | 7 amino acids | |
| Metabolic & weight | FDA-approved | FDA-approved: Ozempic (type 2 diabetes, 2017), Rybelsus (oral, type 2 diabetes, 2019), Wegovy injection… | Not prohibited. Semaglutide markers are tracked under WADA's… | GLP-1 analog peptide with a fatty-acid side chain | |
| Neuro & cognitive | Early human data | Not FDA-approved. | Not named on the 2026 List. Because it is approved in Russia,… | 7 amino acids | |
| Growth hormone axis | FDA-approved | Formerly FDA-approved as Geref (1990 diagnostic; 1997 pediatric GHD); discontinued 2008, approvals withdrawn… | Prohibited at all times (S2.2.4 GHRH and analogues; named) | 29 amino acids (first 29 residues of human GHRH, C-terminal amide) | |
| Metabolic & weight | FDA-approved | FDA-approved as Imcivree (2020) for POMC/PCSK1/LEPR deficiency and Bardet-Biedl syndrome (age 2+), and… | Not listed by name on the 2026 Prohibited List | 8 amino acids (cyclic) | |
| Longevity & mitochondrial | Preclinical only | Not FDA-approved; no human trials found. | Prohibited at all times. On the 2026 list it is not named but falls… | — | |
| Cosmetic & skin | Preclinical only | Not an FDA-approved drug. Sold as a cosmetic ingredient; FDA says products intended to change skin structure… | Not named on the 2026 Prohibited List. | 8 amino acids (N-acetylated, C-terminal amide) | |
| Growth hormone axis | FDA-approved | FDA-approved; first recombinant somatropin (Humatrope) approved 1987, with many brands since. Regulated as a… | Prohibited at all times (S2.2.3: growth hormone, its analogues and… | 191 amino acids (single chain) | |
| Longevity & mitochondrial | FDA-approved | FDA accelerated approval as Forzinity (elamipretide) on September 19, 2025 to improve muscle strength in… | Not named on the 2026 List; as an FDA-approved drug it is not an S0… | 4 amino acids (includes D-arginine and 2,6-dimethyltyrosine) | |
| Metabolic & weight | Late-stage trials | Investigational; not FDA-approved. No FDA submission timeline found in sources reviewed. | Not named on the WADA list; as an unapproved drug it would fall… | Synthetic dual-agonist peptide | |
| Tissue repair | Early human data | Neither TB-500 nor thymosin beta-4 is FDA-approved; RegeneRx's Tβ4 products remain investigational. | Prohibited at all times; S2.3 lists "Thymosin-β4 and its derivatives… | Thymosin beta-4: 43 amino acids (N-terminally acetylated). TB-500 is usually described as the 7-amino-acid fragment LKKTETQ (residues 17-23); product identity varies. | |
| Gastrointestinal | FDA-approved | FDA-approved as Gattex (2012) for short bowel syndrome dependent on parenteral support; REMS eliminated… | Not listed by name on the 2026 Prohibited List | 33 amino acids | |
| Bone & mineral | FDA-approved | FDA-approved (Forteo, 2002; generic and follow-on teriparatide products also exist) for osteoporosis at high… | Not named on the 2026 WADA Prohibited List. | 34 amino acids | |
| Growth hormone axis | FDA-approved | FDA-approved (Egrifta, 2010; Egrifta SV; Egrifta WR, March 2025) for reducing excess abdominal fat in… | Prohibited at all times (S2.2.4 GHRH and analogues; named) | 44 amino acids | |
| Hormonal & reproductive | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 4 amino acids | |
| Immune & antimicrobial | Early human data | Not FDA-approved. Not named on the FDA page of bulk substances that may pose significant safety risks in… | Not named on the 2026 WADA Prohibited List. The list's S0 class… | Mixture of short peptides, not a single defined molecule. Its developers report that processing keeps peptides under 10 kDa [3], and that short peptides of up to about ten amino acids, including the dipeptides KE and EW and the tripeptide EDP, have been identified in it [2]. | |
| Immune & antimicrobial | Late-stage trials | Not FDA-approved in the US. Approved as Zadaxin (thymalfasin) in a number of countries outside the US. | Not named on the 2026 Prohibited List. Because it is approved for… | 28 amino acids (N-terminally acetylated) | |
| Immune & antimicrobial | Early human data | No FDA-approved drug containing thymulin was identified. Thymulin acetate appears on FDA's list of bulk drug… | Thymulin is not named in the WADA 2026 Prohibited List (in force… | 9 amino acids (binds one zinc ion) | |
| Metabolic & weight | FDA-approved | FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023; obstructive… | Not prohibited. Tirzepatide markers are tracked under WADA's… | Peptide based on the GIP sequence with a C20 fatty-diacid side chain | |
| Hormonal & reproductive | Late-stage trials | Not FDA-approved; FDA declined emergency use authorization for aviptadil in COVID-19 (second refusal July 1,… | Not named on the 2026 Prohibited List. | 28 amino acids | |
| Cardiovascular & blood | FDA-approved | FDA-approved as Vasostrict (2014) for vasodilatory shock in adults; other approved vasopressin products exist | Not listed by name on the 2026 Prohibited List (desmopressin is… | 9 amino acids (cyclic) | |
| Cardiovascular & blood | Preclinical only | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 3 amino acids | |
| Immune & antimicrobial | Early human data | Not FDA-approved. | Not named on the 2026 List. If it has no current government approval… | 2 amino acids | |
| Bone & mineral | FDA-approved | FDA-approved as Voxzogo (2021, accelerated approval); expanded October 2023 to children of all ages with… | Not named on the 2026 WADA Prohibited List. | 39 amino acids (disulfide bond 23-39) | |
| Pain & nerve | FDA-approved | FDA-approved (Prialt, 2004) for severe chronic pain needing intrathecal therapy. Carries a boxed warning. | Not named on the 2026 WADA Prohibited List. | 25 amino acids (three disulfide bridges: Cys1-Cys16, Cys8-Cys20, Cys15-Cys25; C-terminal amide) |